Spherix has been tracking the C3G market for over four years in both the U.S. and Europe. The studies have provided meaningful insights into physician perceptions of unmet needs and expectations for ...

With evidence from 85,373 participants across 11 trials, GLP-1 receptor agonists significantly reduced kidney failure risk and cardiovascular events, showing consistent benefits across diabetes ...

This is the first study to show a clear benefit of GLP-1 receptor agonists on kidney failure or end-stage kidney disease, suggesting they have a key role in kidney-protective and heart-protective ...

EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare, progressive kidney disease characterized by inflammation and kidney damage. Patients with C3G often experience ...

(Picture: Waitrose/Cadbury) Shoppers said they were ‘agitated’ by the lack of their festive favourites, and @rmckaysmith even went as far as to say they ‘would absolutely sell [their] kidney ...

Kidney failure occurs when your kidneys lose the ability to filter waste from your blood sufficiently. It may not cause symptoms in the early stages. Your kidneys filter your blood and remove ...

CKM syndrome was identified as a medical condition with the presence of metabolic risk factors, cardiovascular disease, and chronic kidney disease, and was classified into five stages (stage 0–4) in ...

Updated results from the APPEAR-C3G trial – reported at the American Society of Nephrology (ASN) Kidney Week congress in San Diego over the weekend – showed that Fabhalta (iptacopan ...

Nearly 300,000 bottles of the drug, named Cinacalcet, were recalled and given a Class II recall risk level by the FDA.